Argent BioPharma Limited
RGTLF
$0.0599
$0.011423.51%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 194.80K | 388.80K | 583.70K | 729.70K | 881.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 194.80K | 388.80K | 583.70K | 729.70K | 881.50K |
| Cost of Revenue | 442.30K | 612.90K | 784.20K | 767.00K | 754.90K |
| Gross Profit | -247.40K | -224.00K | -200.50K | -37.30K | 126.60K |
| SG&A Expenses | 10.97M | 10.40M | 9.77M | 8.75M | 7.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -795.40K | -951.50K | -1.11M | -1.02M | -933.30K |
| Total Operating Expenses | 12.56M | 12.17M | 11.71M | 11.00M | 10.36M |
| Operating Income | -12.37M | -11.78M | -11.13M | -10.27M | -9.48M |
| Income Before Tax | -14.92M | -13.27M | -11.52M | -11.43M | -11.43M |
| Income Tax Expenses | -- | -- | -- | 0.00 | 0.00 |
| Earnings from Continuing Operations | -14.92 | -13.27 | -11.52 | -11.43 | -11.43 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 200.00 | 6.00K | 11.80K | 51.40K | 91.90K |
| Net Income | -14.92M | -13.26M | -11.50M | -11.38M | -11.34M |
| EBIT | -12.37M | -11.78M | -11.13M | -10.27M | -9.48M |
| EBITDA | -11.69M | -11.09M | -10.42M | -9.61M | -8.86M |
| EPS Basic | -0.29 | -0.32 | -0.34 | -1.27 | -2.23 |
| Normalized Basic EPS | -0.15 | -0.19 | -0.22 | -0.72 | -1.23 |
| EPS Diluted | -0.29 | -0.32 | -0.34 | -1.28 | -2.25 |
| Normalized Diluted EPS | -0.15 | -0.19 | -0.22 | -0.72 | -1.23 |
| Average Basic Shares Outstanding | 203.21M | 175.63M | 148.05M | 100.42M | 52.80M |
| Average Diluted Shares Outstanding | 203.21M | 175.63M | 148.05M | 100.42M | 52.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |